1. Intra-CSF administration of chemotherapy medications

   • Michael P. Gabay
   • Jigisha P. Thakkar
   • J. Lee Villano

   Review Article 03 June 2012 Pages: 1 - 15

2. Tumor and non-tumor tissues differential oxidative stress response to supplemental DHA and chemotherapy in rats

   • Nawale Hajjaji
   • Pierre Besson
   • Philippe Bougnoux

   Original Article 18 May 2012 Pages: 17 - 23

   

3. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53

   • E. Gabriela Chiorean
   • Sonal Sanghani
   • Higinia Cardenes

   Original Article 18 May 2012 Pages: 25 - 32

   

4. Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies

   • Muneaki Shimada
   • Hiroyuki Fujiwara
   • Junzo Kigawa

   Original Article 18 May 2012 Pages: 33 - 38

   

5. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

   • Hannelouise Kissow
   • Niels-Erik Viby
   • Steen Seier Poulsen

   Original Article 22 May 2012 Pages: 39 - 48

   

6. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes

   • Maryam B. Lustberg
   • Shubham Pant
   • Charles L. Shapiro

   Original Article 22 May 2012 Pages: 49 - 56

   

7. Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors

   • Jin Li
   • Yanfei Liu
   • Michiyuki Usami

   Original Article 22 May 2012 Pages: 57 - 63

   

8. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

   • S. Leong
   • S. G. Eckhardt
   • A. C. Lockhart

   Original Article 24 May 2012 Pages: 65 - 74

   

9. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy

   • Solai Elango Damodaran
   • Suresh Chandra Pradhan
   • Chandrasekaran Adithan

   Original Article 24 May 2012 Pages: 75 - 81

   

10. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group

    • Alena Y. Z. Edwards
    • Jeffrey M. Skolnik
    • Jeffrey S. Barrett

    Original Article 24 May 2012 Pages: 83 - 94

    

11. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

    • Gordana Vlahovic
    • Kellen L. Meadows
    • Herbert I. Hurwitz

    Original Article 26 May 2012 Pages: 95 - 102

12. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

    • Yazdi K. Pithavala
    • Ying Chen
    • Michael A. Tortorici

    Original Article 27 May 2012 Pages: 103 - 112

    

13. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

    • B. A. Kamen
    • A. K. Smith

    Original Article 27 May 2012 Pages: 113 - 120

    

14. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

    • Matthew G. Fury
    • Eric Sherman
    • David G. Pfister

    Original Article 27 May 2012 Pages: 121 - 128

15. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas

    • Rachel Grossman
    • Michelle A. Rudek
    • Jaishri O. Blakeley

    Original Article 27 May 2012 Pages: 129 - 139

    

16. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

    • Mohamad Farid
    • Balram Chowbay
    • Simon Yew Kuang Ong

    Original Article 31 May 2012 Pages: 141 - 150

    

17. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics

    • Pradeep B. Lukka
    • James W. Paxton
    • Bruce C. Baguley

    Original Article 03 June 2012 Pages: 151 - 160

    

18. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

    • N. Kentepozidis
    • A. Soultati
    • V. Georgoulias

    Original Article 03 June 2012 Pages: 161 - 168

    

19. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

    • N. Karachaliou
    • N. Ziras
    • D. Mavroudis

    Original Article 06 June 2012 Pages: 169 - 176

20. The minimal impact of food on the pharmacokinetics of ridaforolimus

    • Mark Stroh
    • Xiaodong Li
    • Marian Iwamoto

    Original Article 06 June 2012 Pages: 177 - 182

    

21. Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers

    • Gavin Choy
    • Rajashree Joshi-Hangal
    • Sanjeev Redkar

    Clinical Trial Report 15 February 2012 Pages: 183 - 190

    

22. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor

    • Richat Abbas
    • Bruce A. Hug
    • Daryl Sonnichsen

    Clinical Trial Report 15 March 2012 Pages: 191 - 199

    

23. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors

    • Abdulateef O. Aregbe
    • Eric A. Sherer
    • Robert R. Bies

    Short Communication Open access 27 March 2012 Pages: 201 - 205

24. The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

    • Trevor G. Glaros
    • Luke H. Stockwin
    • Dianne L. Newton

    Short Communication 21 April 2012 Pages: 207 - 212